This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
UK Health Technology Assessment body raises questions over the clinical and cost-effectiveness of Spravato (esketamine).
The scope and validity of this patent will depend on how x-ray diffraction data is interpreted.
A look into the promising potential of artificial intelligence in tackling unmet medical needs in mental healthcare
Nasal spray formulations could offer precision dosing of a spectrum of psychedelic mushroom compounds to consumers.
Market introduction of psychedelics as a therapy looks promising. However, policy and regulatory issues concerning the drug class still exist.
This is the first time psilocybin has been produced from a prokaryotic organism.
Scientific and public opinion is slowly shifting for the potential usage of psilocybin in a variety of conditions. Can the same be said for recreational usage?
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.